Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088392406> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W3088392406 endingPage "S388" @default.
- W3088392406 startingPage "S387" @default.
- W3088392406 abstract "TNBC has a high unmet need for novel therapies. Taxanes (T) are effective in advanced TNBC, but resistance often develops. PI3K pathway hyperactivation, driven by PIK3CA mutations and PTEN loss, can confer resistance to chemotherapy. ALP is an α-selective PI3K inhibitor (i). In SOLAR-1, ALP + fulvestrant prolonged progression-free survival (PFS) vs. PBO + fulvestrant in HR+, HER2–, PIK3CA-mutated advanced breast cancer (ABC). The combination of ALP + nab-PTX demonstrated promising activity in HER2– ABC in a phase I/II trial, which included TNBC patients. EPIK-B3 is a phase III trial in 3 parts evaluating ALP + nab-PTX as 1st or 2nd line of therapy (LoT) in advanced TNBC according to PIK3CA and PTEN status. Part A is a randomised, DB, PBO-controlled study in patients with PIK3CA mutation regardless of PTEN status. Part B1 is a single-arm, open-label study in patients with PTEN loss without PIK3CA mutation, and if preliminary efficacy is demonstrated, Part B2 will explore ALP + nab-PTX in the same patient population as Part B1 in a randomised, DB fashion. Key inclusion criteria are histologic diagnosis of advanced TNBC, ≤1 LoT for advanced disease, and measurable disease or either lytic/mixed lytic-blastic bone lesion with soft tissue component. Prior T therapy is allowed if treatment was completed ≥12 months to Day (D) 1 of Cycle 1, and best response was not progression. Key exclusion criteria are prior PI3Ki/mTORi/AKTi, clinically unstable CNS disease and/or type 1 or uncontrolled type 2 diabetes. In Parts A and B2, patients are randomised 1:1 to receive ALP or PBO + nab-PTX, stratified by metastatic LoT, HR status at initial breast cancer diagnosis, and prior immune checkpoint inhibitor therapy. ALP or PBO is given at 300 mg daily and nab-PTX at 100 mg/m2 IV on D1, 8, and 15 in 28-D cycles. For Parts A and B2, the primary endpoint is PFS with overall survival as a key secondary endpoint. For Part B1, best overall response after 6 months is the primary endpoint. Other endpoints include efficacy, safety, quality of life, and genomic biomarkers. NCT04251533. Medical editorial assistance was provided by Karlo Dumaup, from Healthcare Consultancy Group, LLC, funded by Novartis Pharmaceuticals. Novartis Pharmaceuticals Corporation. Novartis Pharmaceuticals Corporation." @default.
- W3088392406 created "2020-10-01" @default.
- W3088392406 creator A5001814176 @default.
- W3088392406 creator A5010278367 @default.
- W3088392406 creator A5011383890 @default.
- W3088392406 creator A5017728105 @default.
- W3088392406 creator A5022422153 @default.
- W3088392406 creator A5022759974 @default.
- W3088392406 creator A5023674071 @default.
- W3088392406 creator A5025014929 @default.
- W3088392406 creator A5030335115 @default.
- W3088392406 creator A5032293735 @default.
- W3088392406 creator A5060143828 @default.
- W3088392406 creator A5070928275 @default.
- W3088392406 creator A5089513581 @default.
- W3088392406 date "2020-09-01" @default.
- W3088392406 modified "2023-10-05" @default.
- W3088392406 title "349TiP EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation" @default.
- W3088392406 doi "https://doi.org/10.1016/j.annonc.2020.08.451" @default.
- W3088392406 hasPublicationYear "2020" @default.
- W3088392406 type Work @default.
- W3088392406 sameAs 3088392406 @default.
- W3088392406 citedByCount "2" @default.
- W3088392406 countsByYear W30883924062022 @default.
- W3088392406 crossrefType "journal-article" @default.
- W3088392406 hasAuthorship W3088392406A5001814176 @default.
- W3088392406 hasAuthorship W3088392406A5010278367 @default.
- W3088392406 hasAuthorship W3088392406A5011383890 @default.
- W3088392406 hasAuthorship W3088392406A5017728105 @default.
- W3088392406 hasAuthorship W3088392406A5022422153 @default.
- W3088392406 hasAuthorship W3088392406A5022759974 @default.
- W3088392406 hasAuthorship W3088392406A5023674071 @default.
- W3088392406 hasAuthorship W3088392406A5025014929 @default.
- W3088392406 hasAuthorship W3088392406A5030335115 @default.
- W3088392406 hasAuthorship W3088392406A5032293735 @default.
- W3088392406 hasAuthorship W3088392406A5060143828 @default.
- W3088392406 hasAuthorship W3088392406A5070928275 @default.
- W3088392406 hasAuthorship W3088392406A5089513581 @default.
- W3088392406 hasBestOaLocation W30883924061 @default.
- W3088392406 hasConcept C121608353 @default.
- W3088392406 hasConcept C126322002 @default.
- W3088392406 hasConcept C143998085 @default.
- W3088392406 hasConcept C185592680 @default.
- W3088392406 hasConcept C190283241 @default.
- W3088392406 hasConcept C2777176818 @default.
- W3088392406 hasConcept C2777609662 @default.
- W3088392406 hasConcept C2780110267 @default.
- W3088392406 hasConcept C2780482068 @default.
- W3088392406 hasConcept C2908647359 @default.
- W3088392406 hasConcept C502942594 @default.
- W3088392406 hasConcept C530470458 @default.
- W3088392406 hasConcept C55493867 @default.
- W3088392406 hasConcept C71924100 @default.
- W3088392406 hasConcept C86554907 @default.
- W3088392406 hasConcept C99454951 @default.
- W3088392406 hasConceptScore W3088392406C121608353 @default.
- W3088392406 hasConceptScore W3088392406C126322002 @default.
- W3088392406 hasConceptScore W3088392406C143998085 @default.
- W3088392406 hasConceptScore W3088392406C185592680 @default.
- W3088392406 hasConceptScore W3088392406C190283241 @default.
- W3088392406 hasConceptScore W3088392406C2777176818 @default.
- W3088392406 hasConceptScore W3088392406C2777609662 @default.
- W3088392406 hasConceptScore W3088392406C2780110267 @default.
- W3088392406 hasConceptScore W3088392406C2780482068 @default.
- W3088392406 hasConceptScore W3088392406C2908647359 @default.
- W3088392406 hasConceptScore W3088392406C502942594 @default.
- W3088392406 hasConceptScore W3088392406C530470458 @default.
- W3088392406 hasConceptScore W3088392406C55493867 @default.
- W3088392406 hasConceptScore W3088392406C71924100 @default.
- W3088392406 hasConceptScore W3088392406C86554907 @default.
- W3088392406 hasConceptScore W3088392406C99454951 @default.
- W3088392406 hasFunder F4320310388 @default.
- W3088392406 hasLocation W30883924061 @default.
- W3088392406 hasOpenAccess W3088392406 @default.
- W3088392406 hasPrimaryLocation W30883924061 @default.
- W3088392406 hasRelatedWork W1992367938 @default.
- W3088392406 hasRelatedWork W1999292713 @default.
- W3088392406 hasRelatedWork W2109763600 @default.
- W3088392406 hasRelatedWork W2554176272 @default.
- W3088392406 hasRelatedWork W2792929645 @default.
- W3088392406 hasRelatedWork W3095081231 @default.
- W3088392406 hasRelatedWork W4205889393 @default.
- W3088392406 hasRelatedWork W4206087364 @default.
- W3088392406 hasRelatedWork W4283691361 @default.
- W3088392406 hasRelatedWork W4308068357 @default.
- W3088392406 hasVolume "31" @default.
- W3088392406 isParatext "false" @default.
- W3088392406 isRetracted "false" @default.
- W3088392406 magId "3088392406" @default.
- W3088392406 workType "article" @default.